INDAR

Indar is a prominent Ukrainian biopharmaceutical company recognized for its full-cycle production of genetically engineered human insulin. Established in 1997 and headquartered in Kyiv, the company operates one of the few facilities in the world capable of manufacturing insulin from the raw substance to the final dosage form. Indar's product portfolio primarily focuses on diabetes management under the brand name Humodar, but also extends to treatments for tuberculosis and other critical health conditions. The company is a strategic asset for the Ukrainian healthcare system and maintains a significant presence in international export markets across Asia, Africa, and Latin America.